Results 151 to 160 of about 11,904 (210)

Design, synthesis and biological evaluation of novel 3,4-dihydro-2(1<i>H</i>)-quinoline-<i>O</i>-carbamate derivatives as AChE/MAO-B dual inhibitors for the treatment of Alzheimer's disease. [PDF]

RSC Med Chem
Fu W, Wang K, Chen H, Liu T, Liu X, Jin Q, Tan Z, Dong W, Liu W, Sang Z.   +9 more
europepmc   +1 more source

Recurrent Cholinergic Crisis Caused by Therapeutic-Dose Rivastigmine Patch in an Elderly Patient With Alzheimer's Disease: A Case Report. [PDF]

Cureus
Matsuura K, Mayahara T, Katayama T, Arai H.   +3 more
europepmc   +1 more source

Efficacy of cholinesterase inhibitors and memantine on symptoms not responsive to levodopa in patients affected by Parkinson's disease without dementia: a systematic review. [PDF]

BMJ Neurol Open
Cani I, Grotteschi N, Calandra-Buonaura G, Guarino M, Guaraldi P, Giannini G, Baldelli L, Donati M, Cortelli P, Camerlingo MD, Nonino F, Sambati L.   +11 more
europepmc   +1 more source

Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trials. [PDF]

Syst Rev
Abouelmagd ME, Almosilhy NA, Makhlouf HA, Hassan AK, Osman ASA, Hindawi MD, Elshahat A, Alnajjar AZ, Mustafa MMM, Abdelsalam OK, Mady A, Shaheen A, Barrett MJ, Negida A.   +13 more
europepmc   +1 more source

Computational Identification of Potent Multitarget Natural Ligands for Alzheimer's Disease Therapeutics. [PDF]

Scientifica (Cairo)
Sharif N, Bibi A, Sadiq R, Ullah I, Rauf A, Arshad MT, Bashir S, Zamir H, Gull S, Anwar T, Laryea E.   +10 more
europepmc   +1 more source

Editorial: Cognition in Parkinson's disease. [PDF]

Front Cognit
Kalbe E, Jost WH.
europepmc   +1 more source

Erratum. [PDF]

Arq Neuropsiquiatr
europepmc   +1 more source